{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:21:20Z","timestamp":1756383680208,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We report a case of sudden, lethal metabolic acidosis in a 70-year-old man on long-term nucleoside reverse transcriptase inhibitor (NRTI) -based antiretroviral therapy (ART) who had developed atypical necrotizing fasciitis 1\u00a0month after kidney transplantation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The HIV infection of the patient was treated for the last four months with an integrase strand inhibitor (dolutegravir 50\u00a0mg\/d) plus a NRTI backbone including lamivudine (150\u00a0mg\/d) and abacavir (600\u00a0mg\/d). In this renal transplant patient we hypothesize that the co-existence of sepsis, renal failure and an accumulation of lamivudine led to the development of fatal metabolic acidosis and hyperlactatemia. Although lamivudine is only rarely associated with hyperlactatemia, there is evidence that overdose may be a risk factor for developing it. In our patient the lamivudine concentration two days after stopping and during hemodiafiltration was more than 50 times higher than therapeutic target trough concentrations. Likely reasons for this were renal impairment and concurrent treatment with trimethoprim, known to inhibit the renal elimination of lamivudine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>NRTIs could trigger the development of hyperlactatemia in septic patients. The use of NRTI sparing regimens might be considered in the presence of this critical condition.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-021-00382-8","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T12:02:48Z","timestamp":1630756968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient\u2014a case report and review of the literature"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-1652","authenticated-orcid":false,"given":"Alexa","family":"Hollinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Cueni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catia","family":"Marzolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dickenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Landmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Battegay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien Emmanuel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Siegemund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Leuppi-Taegtmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"issue":"3","key":"382_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/088922201750063106","volume":"17","author":"W Tantisiriwat","year":"2001","unstructured":"Tantisiriwat W, Tebas P, Polish LB, et al. Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses. 2001;17(3):195\u2013201.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"382_CR2","doi-asserted-by":"publisher","first-page":"R152","DOI":"10.1186\/cc9221","volume":"14","author":"AM Japiassu","year":"2010","unstructured":"Japiassu AM, Amancio RT, Mesquita EC, et al. Sepsis is a major determinant of outcome in critically ill HIV\/AIDS patients. Crit Care. 2010;14(4):R152.","journal-title":"Crit Care"},{"issue":"6","key":"382_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1086\/339041","volume":"34","author":"V Falco","year":"2002","unstructured":"Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34(6):838\u201346.","journal-title":"Clin Infect Dis"},{"key":"382_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clinms.2018.04.001","volume":"8","author":"PSD Courlet","year":"2018","unstructured":"Courlet PSD, Cavassini M, Du Pasquier R, Alves Saldanha S, Buclin T, Marzolini C, Csajka C, Decosterd L. Determination of nucleosidic\/tidic reverse transcriptase inhibitors in plasma and cere-brospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clin Mass Spectrom. 2018;8:8\u201320.","journal-title":"Clin Mass Spectrom"},{"issue":"3","key":"382_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1128\/AAC.05599-11","volume":"56","author":"LJ Else","year":"2012","unstructured":"Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother. 2012;56(3):1427\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"382_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mito.2014.05.007","volume":"17","author":"M Adeva-Andany","year":"2014","unstructured":"Adeva-Andany M, Lopez-Ojen M, Funcasta-Calderon R, et al. Comprehensive review on lactate metabolism in human health. Mitochondrion. 2014;17:76\u2013100.","journal-title":"Mitochondrion"},{"issue":"3","key":"382_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/cc2162","volume":"7","author":"YE Claessens","year":"2003","unstructured":"Claessens YE, Chiche JD, Mira JP, et al. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care. 2003;7(3):226\u201332.","journal-title":"Crit Care"},{"issue":"44","key":"382_CR8","doi-asserted-by":"publisher","first-page":"40847","DOI":"10.1074\/jbc.M106743200","volume":"276","author":"AA Johnson","year":"2001","unstructured":"Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001;276(44):40847\u201357.","journal-title":"J Biol Chem"},{"issue":"6","key":"382_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3851\/IMP3229","volume":"23","author":"PM van Dam","year":"2018","unstructured":"van Dam PM, van Geffen MW, Havenith TR, et al. Intentional overdose of dolutegravir\/abacavir\/lamivudine (triumeq) in a 26-year-old man. Antivir Ther. 2018;23(6):549\u201352.","journal-title":"Antivir Ther"},{"issue":"6","key":"382_CR10","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1128\/AAC.40.6.1514","volume":"40","author":"AE Heald","year":"1996","unstructured":"Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40(6):1514\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"382_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bcp.2013.07.008","volume":"86","author":"F Muller","year":"2013","unstructured":"Muller F, Konig J, Hoier E, et al. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013;86(6):808\u201315.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"382_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1365-2125.1998.00044.x","volume":"46","author":"MA Johnson","year":"1998","unstructured":"Johnson MA, Verpooten GA, Daniel MJ, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 1998;46(1):21\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"382_CR13","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1128\/AAC.46.8.2387-2392.2002","volume":"46","author":"PR Bohjanen","year":"2002","unstructured":"Bohjanen PR, Johnson MD, Szczech LA, et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother. 2002;46(8):2387\u201392.","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"382_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1097\/00002030-200109070-00012","volume":"15","author":"A Foli","year":"2001","unstructured":"Foli A, Benvenuto F, Piccinini G, et al. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS. 2001;15(13):1687\u201394.","journal-title":"AIDS"},{"key":"382_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00382-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T12:06:14Z","timestamp":1630757174000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00382-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00382-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"type":"electronic","value":"1742-6405"}],"subject":[],"published":{"date-parts":[[2021,9,4]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not seek for approval from an ethics committee. Written consent for publication was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient\u2019s sister has given written consent for publication of this case. Her nephew and his partner are both attorneys and were present when she gave permission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Each of the authors declares that there are no financial or non-financial conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}